JP2016535772A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535772A5
JP2016535772A5 JP2016551466A JP2016551466A JP2016535772A5 JP 2016535772 A5 JP2016535772 A5 JP 2016535772A5 JP 2016551466 A JP2016551466 A JP 2016551466A JP 2016551466 A JP2016551466 A JP 2016551466A JP 2016535772 A5 JP2016535772 A5 JP 2016535772A5
Authority
JP
Japan
Prior art keywords
optionally substituted
group
hydrogen atom
methyl
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016551466A
Other languages
English (en)
Japanese (ja)
Other versions
JP6412148B2 (ja
JP2016535772A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2014/080005 external-priority patent/WO2015068856A1/en
Publication of JP2016535772A publication Critical patent/JP2016535772A/ja
Publication of JP2016535772A5 publication Critical patent/JP2016535772A5/ja
Application granted granted Critical
Publication of JP6412148B2 publication Critical patent/JP6412148B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016551466A 2013-11-08 2014-11-05 自己免疫疾患治療のためのピラゾール Active JP6412148B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2013232571 2013-11-08
JP2013232571 2013-11-08
JP2014128562 2014-06-23
JP2014128562 2014-06-23
PCT/JP2014/080005 WO2015068856A1 (en) 2013-11-08 2014-11-05 Pyrazole for the treatment autoimmune disorders

Publications (3)

Publication Number Publication Date
JP2016535772A JP2016535772A (ja) 2016-11-17
JP2016535772A5 true JP2016535772A5 (enExample) 2017-09-21
JP6412148B2 JP6412148B2 (ja) 2018-10-24

Family

ID=51999482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551466A Active JP6412148B2 (ja) 2013-11-08 2014-11-05 自己免疫疾患治療のためのピラゾール

Country Status (11)

Country Link
US (2) US9321757B2 (enExample)
EP (1) EP3066094B1 (enExample)
JP (1) JP6412148B2 (enExample)
CN (1) CN105899505B (enExample)
BR (1) BR112016010041B1 (enExample)
CA (1) CA2929316C (enExample)
EA (1) EA201690952A1 (enExample)
ES (1) ES2777123T3 (enExample)
TW (1) TW201605847A (enExample)
UY (1) UY35821A (enExample)
WO (1) WO2015068856A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
WO2015068856A1 (en) * 2013-11-08 2015-05-14 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP6936236B2 (ja) * 2016-02-18 2021-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 治療化合物、組成物及びその方法の使用
US10610520B2 (en) 2016-03-31 2020-04-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN106317952B (zh) * 2016-08-19 2018-03-09 福建中烟工业有限责任公司 一种增白组合物、其制备方法及用途
JP2019196309A (ja) * 2016-09-15 2019-11-14 武田薬品工業株式会社 複素環化合物
ES2946001T3 (es) * 2016-10-26 2023-07-11 Rigel Pharmaceuticals Inc Compuestos de pirazol amida como inhibidores de IRAK
TWI733982B (zh) 2017-02-16 2021-07-21 美商基利科學股份有限公司 吡咯并[1,2-b]嗒衍生物
EP3596072B1 (en) * 2017-03-14 2022-06-22 F. Hoffmann-La Roche AG Pyrazolochlorophenyl compounds, compositions and methods of use thereof
WO2018215389A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
JP7366031B2 (ja) 2017-09-22 2023-10-20 カイメラ セラピューティクス， インコーポレイテッド タンパク質分解剤およびそれらの使用
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
MX2020009234A (es) 2018-04-05 2020-10-12 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
EP3553061A1 (en) * 2018-04-12 2019-10-16 Centre National De La Recherche Scientifique (Cnrs) New inhibitors of bone resorption
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CA3224985C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR102625224B1 (ko) 2018-10-31 2024-01-15 주식회사 큐로젠 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP2023500707A (ja) * 2019-11-05 2023-01-10 デルミラ インコーポレイテッド 炎症を特徴とする皮膚科状態の治療に使用するためのｉｒａｋ４阻害剤を含む局所用組成物
EP4072591A4 (en) 2019-12-10 2024-06-05 Kymera Therapeutics, Inc. IRAQ DEGRADER AND USES THEREOF
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP2023509366A (ja) 2019-12-17 2023-03-08 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
IL298929A (en) * 2020-06-30 2023-02-01 Dermira Inc IRAK4 inhibitors and their topical uses
WO2022147465A1 (en) 2020-12-30 2022-07-07 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TW202245788A (zh) 2021-02-15 2022-12-01 美商凱麥拉醫療公司 Irak4降解劑及其用途
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
EP4422635A4 (en) 2021-10-29 2025-11-26 Kymera Therapeutics Inc IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
IL314437A (en) 2022-01-31 2024-09-01 Kymera Therapeutics Inc IRAK joints and their uses
US12384775B2 (en) 2022-03-23 2025-08-12 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006070198A1 (en) * 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
MX2009004786A (es) * 2006-10-31 2009-06-05 Schering Corp Derivados de anilinopiperazina y sus metodos de uso.
EP2070924A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
JP2012254939A (ja) 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
EA201290957A1 (ru) * 2010-04-07 2013-04-30 Ф.Хоффманн-Ля Рош Аг Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения
WO2015068856A1 (en) * 2013-11-08 2015-05-14 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders

Similar Documents

Publication Publication Date Title
JP2018519323A5 (enExample)
JP2016530310A5 (enExample)
JP2016536363A5 (enExample)
JP2016540811A5 (enExample)
CA2796967A1 (en) Heterocyclic derivatives as alk inhibitors
JP2017513894A5 (enExample)
JP2016536364A5 (enExample)
JP2017214387A5 (enExample)
JP2015501799A5 (enExample)
JP2014511869A5 (enExample)
JP2010506825A5 (enExample)
HRP20170112T1 (hr) Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze
EA201270676A1 (ru) Полиморфная, кристаллическая и мезофазная формы 2-(5-бром-4-(4-циклопропилнафталинил-1-ил)-4н-1,2,4-триазол-3- илтио)ацетата натрия и их применение
JP2016537389A5 (enExample)
JP7368365B2 (ja) Ｐ３００／ｃｂｐ ｈａｔ阻害剤及びそれらの使用の方法
JP2016530322A5 (enExample)
JP2013531074A5 (enExample)
JP2016528273A5 (enExample)
BR112016010041A2 (pt) composto, medicamento, e, uso do composto ou sal
JP2015535851A5 (enExample)
JP2017508733A5 (enExample)
JP2020500916A5 (enExample)
JP2016529235A5 (enExample)
JP2017517538A5 (enExample)
NZ629636A (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions